ArticleCommunications chemistry2026
Design of benzo[1,2-b:4,3-b']dithiophene-4,5-dione based donor-acceptor-donor small molecules for efficient near-infrared photothermal therapy.
Article in Communications chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Substituent-controlled electronic redistribution and nonlinear optical response across the Ag-S interface in W@AgJournal of molecular modeling · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of high-performance organic photothermal conversion agents (PTCAs) with strong near-infrared (NIR) absorption, high photothermal conversion efficiency (PCE), and excellent biocompatibility remains a critical challenge in photothermal therapy (PTT). In this study, we designed and synthesized a series of novel donor-acceptor-donor (D-A-D) small molecules based on a benzo[1,2-b:4,3-b']dithiophene-4,5-dione (BDTD-4,5-dione) core as a strong electron-accepting unit, symmetrically functionalized with triphenylamine (TPA) derivatives as tunable electron donors. By focusing on the strong electron-donating N,N-dimethylaniline (NPA) unit-contrasted with a methoxy-substituted analog-we achieved effective modulation of the HOMO energy, bandgap, and supramolecular aggregation, underscoring the advantage of enhanced donor strength for photothermal applications. Spectroscopic and electrochemical analyses revealed that electron-rich substituents significantly redshifted the intramolecular charge transfer (ICT) absorption into the NIR region (650-900 nm) and enhanced molar extinction coefficients. Among the derivatives, the dimethylamino-functionalized compound (BDQ-NPA) exhibited the most redshifted absorption, a narrow bandgap (2.0 eV), and an outstanding PCE of 35.05% under 808 nm laser irradiation. Theoretical calculations confirmed strong D-A interactions and efficient charge separation in the excited state. BDQ-NPA self-assembled into stable nanoparticles with excellent photostability and biocompatibility, facilitating efficient cellular uptake and NIR-triggered photothermal ablation of cancer cells in vitro. In vivo studies demonstrated significant tumor growth inhibition in a murine model following a single dose of BDQ-NPA and 808 nm irradiation, with no observable systemic toxicity. This work establishes BDTD-4,5-dione as a promising acceptor core for NIR-absorbing organic PTCAs and highlights the efficacy of substituent engineering in optimizing photothermal performance for cancer theranostics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.